Novartis provides healthcare solutions that address the evolving needs of patients and societies products to prevent and treat diseases, ease suffering and enhance quality of life.
The Novartis portfolio focuses on science-based healthcare sectors that are growing and reward innovation, such as pharmaceuticals, eye care, generics, vaccines and diagnostics, over-the-counter (OTC) and animal health.
Novartis is the only company with leading positions in each of these areas. Novartis research is driven by a distinctive clinical and scientific strategy focusing on unmet medical need and knowledge of disease.
Corporate social responsibility is an integral part of how Novartis operates and key to our success. We focus on improving access to healthcare globally, and our Malaria Initia... (Source: SEC reports)
Competitor - 1/8
Which company is more competitive with Novartis Corporation?
EAST HANOVER, N.J., July 12, 2017 /PRNewswire/ --Â Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel), [...]
EAST HANOVER, N.J., June 23, 2017 /PRNewswire/ -- Novartis todayÂ announced updated results from the ELIANA clinical trial demonstrating CTL019 (tisagenlecleucel) remission rates are maintained at six months in relapsed/refractory (r/r) [...]
EAST HANOVER, N.J., June 7, 2017 /PRNewswire/ --Â Novartis announced findings from an interim analysis of its multi-center Phase II JULIET study (NCT02445248) of CTL019 (tisagenlecleucel) in adult patients with relapsed [...]
EAST HANOVER, N.J. , June 5, 2017 /PRNewswire/ -- Novartis today announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and [...]